SCHEMBL13256286

SCHEMBL13256286

O=C(Nc1nc2[nH]nc(-c3ccccc3)c2s1)c1ccno1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.46
KMT2A Q03164 5/20 0.45
MEN1 O00255 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
ADORA2A P29274 12/20 0.44
ADORA1 P30542 10/20 0.44
ADORA3 P0DMS8 6/20 0.44
ADORA2B P29275 3/20 0.44
ALDH1A1 P00352 2/20 0.44
ESR1 P03372 1/20 0.44
POLB P06746 1/20 0.44
ESR2 Q92731 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13256296 0.83 HPGD (0.66) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL18953017 0.81 ADORA2A (0.65) HDAC1KMT2AMEN1NPC1RAB9A
SCHEMBL3500537 0.80 PARP1 (0.54) KMT2ANPC1RAB9ASMN1; SMN2ADORA2A
SCHEMBL13256166 0.78 ALDH1A1 (0.53) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL13256284 0.78 F2 (0.54) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL13256182 0.77 ADORA3 (0.46) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL13256304 0.77 RAB9A (0.65) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL13283501 0.75 ADORA3 (0.49) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL13256173 0.74 PTGDR2 (0.61) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL13256179 0.74 RAB9A (0.50) KMT2AMEN1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS MAP3K20, MAP4K2, MAP4K3 HDAC1 681/4885KMT2A 1583/4885MEN1 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.